You are here: Industry Insights > tumour

News List

OncoOne launches with €13m Series A funding pharmaceutical-technology
March 19, 2020
Austria-based OncoOne closed its Series A funding round with €13m raised. This financing will be used to officially launch the company and support the development of oncology treatments...
Nanocarrier could revolutionise chemotherapy drug delivery europeanpharmaceuticalreview
March 04, 2020
Scientists have developed an innovative nanocarrier that can selectively target and deliver a chemotherapy payload to cancer cells without adverse effects on healthy cells.
NICE argue for more histology-independent cancer drug evidence europeanpharmaceuticalreview
January 13, 2020
Staff at NICE have co-authored a paper which suggests that new, histology-independent cancer treatments require more clinical evidence before approval recommendation by the institution.
Publication of First In-Human Data Reveals Safety & Efficacy of Tigilanol Tiglate in Solid Tumours En-CPhI.CN
December 10, 2019
Australian life sciences company, QBiotics Group Limited (QBiotics) is announcing the publication[1] of positive results from a first in-human Phase I clinical trial of ...
Researchers use three-drug combination to treat lung cancer pharmaceutical-technology
September 26, 2019
A study by the Francis Crick Institute and The Institute of Cancer Research, London has tested the combination of a G12C KRAS inhibitor with mTOR and IGF1R inhibitors for the treatment of lung cancer.
SpringWorks receives breakthrough status for desmoid tumour drug pharmaceutical-technology
September 03, 2019
SpringWorks Therapeutics has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for nirogacestat...
Study shows the potential to deliver immunotherapy directly to brain tumours europeanpharmaceuticalreview
September 02, 2019
New nano-immunotherapy has traversed the blood-brain barrier in mice, inducing an immune response in brain tissue surrounding tumours.
Roche's first FDA-approved tumour-agnostic medicine worldpharmanews
August 19, 2019
Roche announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC).
New system delivers drug straight into tumours with fewer side effects europeanpharmaceuticalreview
July 22, 2019
A new drug delivery system disguises chemo-therapeutics as fat in order to destroy tumours.
Bristol-Myers Squibb and Infinity to collaborate on Opdivo (nivolumab) plus IPI-549 solid tumours study europeanpharmaceuticalreview
May 08, 2019
Bristol-Myers Squibb and Infinity will collaborate on a solid tumours trial to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s…

Previous page 1 2 3 4 5 Next page